Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)


Por: Lluch A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano A, Garcia-Saenz J, Torres R, de la Haba J, Garcia-Martinez E, Gomez H, Llombart A, Bofill J, Baena-Canada J, Barnadas A, Calvo L, Perez-Michel L, Ramos M, Fernandez I, Rodriguez-Lescure A, Cardenas J, Vinholes J, de Duenas E, Godes M, Segui M, Anton A, Lopez-Alvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero M, Bezares S, Carrasco E, Martin M, Corona J, Jara C, Cardemil B, Toro R, Pimentel C, Hernando B, Vicente E, Zagame L, Gil M, Estevez L, Rodriguez C, de la Cruz M, Tello J, Campos S, Lomas M, Capdevile D, Campos M, Margeli M, Andres R, Tusquets I, Ballesteros A, Guerrero A, Arguello M, Rodriguez J, Munoz M, Florian J, Azevedo S, Mondragon R, Peralta J, Palomo A, Barajas L, Arcusa A, Carranza H, Garcia C, Umbria C, Ales J, Vega J, Romeo M, Valero J, Alonso J, Mathias C, Gutierrez F, Adrover E, Nunez P, Mendiola C, Cassinello J, de la Huerta A, Geicam Spanish Breast Canc Grp, CIBOMA Iberoamer Coalition Res Bre, LACOG

Publicada: 20 ene 2020
Resumen:
PURPOSE Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. PATIENTS AND METHODS Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free survival (DFS) between both arms. RESULTS Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3 years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P = .136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype (interaction test P = .0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (interaction test P = .0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles. CONCLUSION This study failed to show a statistically significant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal phenotype seemed to obtain benefit with capecitabine, although this will require additional validation. (C) 2019 by American Society of Clinical Oncology

Filiaciones:
Lluch A:
 Univ Valencia, Hosp Clin Univ Valencia, Valencia, Spain

 Univ Valencia, Biomed Res Inst INCLIVA, Valencia, Spain

 Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain

 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Barrios C:
 Ctr Pesquisa Clfn Hosp Sao Lucas PUCRS, Porto Alegre, RS, Brazil

 LACOG, Porto Alegre, RS, Brazil

Torrecillas L:
 Ctr Med Nacl 20 Noviembre, Inst Seguridad & Serv Sociales Trabajadores Estad, Ciudad De Mexico, Mexico

Ruiz-Borrego M:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ Virgen Rocio, Seville, Spain

Bines J:
 LACOG, Porto Alegre, RS, Brazil

 Inst Nacl Canc, Rio De Janeiro, Brazil

Segalla J:
 LACOG, Porto Alegre, RS, Brazil

 Hosp Amaral Carvalho, Sao Paulo, Brazil

Guerrero-Zotano A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Inst Valenciano Oncol, Valencia, Spain

Garcia-Saenz J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Clin San Carlos, Madrid, Spain

Torres R:
 Inst Nacl Canc, Santiago, Chile

de la Haba J:
 Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain

 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ Reina Sofia, Cordoba, Spain

Garcia-Martinez E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Gen Univ Morales Meseguer, Murcia, Spain

Gomez H:
 Inst Nacl Enfermedades Neoplas, Lima, Peru

 Peruvian Oncol Clin Studies Grp, GECOPERU, Lima, Peru

Llombart A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Arnau Vilanova, Lleida, Spain

Bofill J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ NS Valme, Seville, Spain

Baena-Canada J:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ Puerta Mar, Cadiz, Spain

 Inst Invest & Innovac Biomed Cadiz, Cadiz, Spain

Barnadas A:
 Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain

 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Univ Autonoma Barcelona, Inst Recerca Biomed St Pau, Med Dept, Hosp Santa Creu & St Pau, Barcelona, Spain

Calvo L:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Complexo Hosp Univ A Coruna, La Coruna, Spain

Perez-Michel L:
 Hosp San Jose, Obregon, Sonora, Mexico

Ramos M:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Ctr Oncol Galicia, La Coruna, Spain

Fernandez I:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Complexo Hosp Univ Vigo, Vigo, Spain

Rodriguez-Lescure A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Gen Univ Elche, Alicante, Spain

Cardenas J:
 Ctr Med Colima, Colima, Mexico

Vinholes J:
 LACOG, Porto Alegre, RS, Brazil

 Unidade Novos Tratamentos CliniOnco, Porto Alegre, RS, Brazil

de Duenas E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Godes M:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Gen Univ Valencia, Valencia, Spain

Segui M:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Corporacio Sanitaria Parc Tauli Sabadell, Barcelona, Spain

Anton A:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon, Zaragoza, Spain

Lopez-Alvarez P:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain

Moncayo J:
 Social S Hosp Teodoro Maldonado Carbo, Guayaquil, Ecuador

Amorim G:
 LACOG, Porto Alegre, RS, Brazil

 Oncol DOr, Rio De Janeiro, Brazil

Villar E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Hosp Reg Univ Carlos Haya, Malaga, Spain

Reyes S:
 Hosp Beneficiencia Espanola, San Luis Potosi, Mexico

Sampaio C:
 LACOG, Porto Alegre, RS, Brazil

 Clin Amo Itaigara, Salvador, BA, Brazil

Cardemil B:
 Hosp Base Valdivia, Valdivia, Chile

Escudero M:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Bezares S:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Carrasco E:
 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

Martin M:
 Ctr Invest Biomed Red Oncol ISCIII, Madrid, Spain

 Spanish Breast Canc Grp, GEICAM, Madrid, Spain

 Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

Cardemil B:
 Hosp Base Valdivia, Valdivia, Chile
ISSN: 0732183X





Journal Of Clinical Oncology
Editorial
AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 38 Número: 3
Páginas: 203
WOS Id: 000508197300005
ID de PubMed: 31804894

MÉTRICAS